AbCellera Partners with Vertex to Develop Multispecific T-Cell Engagers
VANCOUVER, British Columbia, July 29, 2026 AbCellera Biologics Inc. announced a strategic collaboration with Vertex Pharmaceuticals to research, develop,...
TCE
Advertisement
VERAXA Achieves Key Regulatory Milestone for BiTAC-TCE
ZURICH, Switzerland, July 20, 2026 VERAXA Biotech AG (NASDAQ: VRXA) announced that it has received Scientific Advice from Germany’s...
Antengene and UCB Advance ATG-201 Partnership with $60M Payment
SHANGHAI and HONG KONG, China, July 13, 2026 Antengene has announced the receipt of a USD 60 million upfront...
92Bio Doses First Patient in Phase 1 Trial of NTB-928 for Platinum-Resistant Ovarian Cancer
SAN DIEGO, Calif., July 1, 2026 92Bio, Inc. announced that the first patient has been dosed in its Phase...
Mabwell Receives China IND Clearance for 6MW5311 Cancer Therapy
SHANGHAI, June 23, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND)...
Advertisements
Antengene Signs Up to $1.9 Billion TCE Licensing Deal
BOSTON, Singapore and Hong Kong, June 22, 2026 Antengene Corporation Limited has announced a landmark strategic licensing agreement with...
Voro and Alloy Partner on Next-Gen T-Cell Cancer Therapies
SAN DIEGO, Calif. and BOSTON, Mass., June 20, 2026 Voro Therapeutics and Alloy Therapeutics have announced a strategic research...
Antengene Secures China IND Clearance for ATG-201
SHANGHAI and HONG KONG, China, June 10, 2026 Antengene announced that China’s National Medical Products Administration (NMPA) has approved...
Advertisement
